comparemela.com
Home
Live Updates
Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC : comparemela.com
Dr Rini on Sustained Survival Outcomes After Completion of Pembrolizumab and Axitinib in ccRCC
Brian I. Rini, MD, FASCO, discusses long-term survival outcomes in patients with advanced clear cell renal cell carcinoma who received frontline pembrolizumab and axitinib in the phase 3 KEYNOTE-426 trial.
Related Keywords
Briani Rini ,
,
Division Of Hematology Oncology ,
Vanderbilt Ingram University Cancer Center ,
Ingram Professor ,
Hematology Oncology ,
Clinical Trials ,
Vanderbilt Ingram Cancer Center ,
Genitourinary Cancers ,
Onclive Tv ,
Asco 2023 ,
Pembrolizumab ,
Axitinib ,
Renal Cell Carcinoma ,
comparemela.com © 2020. All Rights Reserved.